ACCELERATE BRAIN CANCER CURE INC (EIN 522320756) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2001

Legal Domicile

Principal Officer

MAX WALLACE

Phone

2024193140

Tax Period

2019-01-01 to 2019-12-31

ACCELERATE BRAIN CANCER CURE INC, founded in 2001, is a community nonprofit that reported $1.2M in total revenue in fiscal year 2019. Revenue fell 39% from the prior year — a significant decline worth monitoring. Expenses of $4.0M exceeded revenue, resulting in a 242% operating deficit.

Mission

ACCELERATE BRAIN CANCER CURE HAS A SINGLE FOCUS-TO HASTEN THE DISCOVERY OF A CURE FOR BRAIN CANCER.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2019)

Revenue Breakdown

Contributions & Grants $1,410,344

Program Service Revenue $0

Investment Income $10,019

Other Revenue $-253,652

TOTAL REVENUE $1,166,711

Expense Breakdown

Grants Paid $2,499,437

Salaries & Benefits $1,152,879

Fundraising Expenses $659,418

Program Expenses $2,874,312

Other Expenses $333,783

TOTAL EXPENSES $3,986,099

Year-over-Year Comparison

	2019	2018	Change
Revenue	$1,166,711	$1,915,355	-0.4%
Expenses	$3,986,099	$1,584,284	+1.5%
Net Income	$-2,819,388	$331,071	-9.5%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

300

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$884,489

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
STEVE CASE	CHAIRMAN & CO-FOUNDER	1.00	Officer Director	$0	$0	$0
STACEY CASE	CO-FOUNDER	1.00	Director	$0	$0	$0
NANCY PFUND	MEMBER	1.00	Director	$0	$0	$0
DAVID COLE	MEMBER	1.00	Director	$0	$0	$0
JEAN CASE	CO-FOUNDER	1.00	Director	$0	$0	$0
DOUG HOLLADAY	MEMBER	1.00	Director	$0	$0	$0
JONATHAN WEINBERG	MEMBER	1.00	Director	$0	$0	$0
GARY WIMMER	MEMBER	1.00	Director	$0	$0	$0
MAX WALLACE	PRESIDENT AND CEO	40.00	Officer	$536,539	$16,338	$552,877
DAVID SANDAK	VP/SECRETARY/TREASURER	40.00	Officer	$318,748	$12,864	$331,612

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2019	$1,166,711	$3,986,099	No data	$-2,819,388
2018	$1,915,355	$1,584,284	$3,099,618	$331,071

ACCELERATE BRAIN CANCER CURE INC